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Background: After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma
patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving
inhaled corticosteroids (ICS). We aim to analyse LABA- and ICS-related prescription patterns after the SMART trial in
Germany.
Methods: Patients documented in the Bavarian Association of Statutory Health Insurance Physicians database
(approximately 10.5 million people) were included if they had a diagnosis of asthma and at least one prescription of
LABA and/or ICS between 2004 and 2008. Annual period prevalence rates (PPRs) were estimated and Cochrane
Armitage tests were used for time trend analyses.
Results: Highest annual PPRs were found for budesonide and the fixed combination of salmeterol/fluticasone. The
proportion of “concomitant LABA and ICS users” increased from 52.0 to 57.6% within the study period, whereas for
“LABA users without ICS” a slight decrease from 6.5 to 5.4% was found. In 2008, the proportion of patients with at least
one quarter with a LABA prescription without concomitant ICS was highest in elderly, male patients (≈20%). In the
majority of these patients, a concomitant diagnosis of COPD (i.e. asthma-COPD overlap syndrome [ACOS]) was present.
Conclusions: Between 2004 and 2008, we found a moderate increase in guideline-adherent LABA prescribing in a
representative German population. Elderly men received a significant number of LABA prescriptions without
concomitant ICS probably due to ACOS.
Keywords: Long-acting adrenergic beta-2-receptor agonists, Inhaled corticosteroids, Asthma, COPD, ACOS, Drug
utilisation study, SMART trial, Drug regulatory actionsBackground
The Salmeterol Multicentre Asthma Research Trial
(SMART) [1] was a large randomized controlled trial in
asthma patients evaluating the safety of salmeterol (i.e., a
long-acting beta-2-agonist [LABA]) compared to placebo
in addition to usual asthma care. In 2003, this trial was
prematurely terminated by GlaxoSmithKline due to recruit-
ment problems and safety issues. In an interim analysis, a
non-significant increase in combined respiratory-related
deaths or life-threatening events was found in patients re-
ceiving salmeterol but for African Americans, this increase
was statistically significant. Furthermore, a significantly* Correspondence: marietta.rottenkolber@med.uni-muenchen.de
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unless otherwise stated.increased risk for “combined respiratory-related death or
life-threatening experience” (RR = 5.6, 95% CI: 1.2-25.3)
and “combined asthma-related deaths or life-threatening
experience” (RR = 10.5, 95% CI: 1.3-81.6) was found for Af-
rican Americans who had no prescription of an inhaled
corticosteroid (ICS) at baseline. In contrast, if ICS was
present at baseline no significant differences between pa-
tients receiving salmeterol or placebo were found [1]. Re-
garding these results as well as previously and recently
published guidelines, LABA should be prescribed only to
patients receiving ICS [2,3].
In 2003, “Dear doctor” letters were sent out by Glax-
oSmithKline and detailed results of the SMART trial
were added to the respective SPCs of LABA-containing
products [4-6]. After presentation of SMART results to
the public, an intensive and somewhat controversialentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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2005, information for health care providers were sent
out by the FDA stating that LABA should be prescribed
to asthma patients only if other medicines, including
low-or-medium dose ICS, do not control asthma [8-10]
and a ‘Black box’ warning on LABA was imposed by the
FDA [11,12]. In Germany, the national drug regulatory
authority (“BfArM”) published in August 2003 a state-
ment [13] presenting results of the SMART trial and
pointing out the need for a guideline-adherent treatment
[14]. In 2006, it was decided to add warnings similar to
those made by the FDA to product labelling of LABA
compounds in Germany, too [15].
Taking into account the essential need for a concomi-
tant ICS usage in patients receiving LABA, fixed com-
bination of LABA/ICS might be considered as a
meaningful treatment option for patients with asthma
and respective recommendations were made by the FDA
[16,17] and by several guidelines [3,17,18].
Despite the importance of obtaining a reliable picture
of real-life prescription behaviour after the SMART trial
and related regulatory actions, only a few data exists
analysing changes in LABA- and ICS-related prescribing
in detail [19,20]. Hence, we aim to analyse trends in pre-
scriptions of LABA, ICS, and fixed combination drugs
containing LABA and ICS between 2004 and 2008 using
a German database covering 10.5 million people.
Methods
Study type and data source
A drug utilization study was conducted in the database
of the Association of Statutory Health Insurance Physi-
cians, Bavaria [21]. This population-based database
covers all compulsorily insured persons of the Statutory
Health Insurance. The database has existed since 2001
and covers 85% (i.e., 10.5 million people) of the total
Bavarian population excluding those with a private
health insurance. It compiles, based on accounting infor-
mation of Bavarian physicians, the patient characteris-
tics, diagnoses of both general practitioners and
consultants, all performed medical services, and drug
utilization of all outpatients. Diagnoses and patient char-
acteristics are documented on a patient-related basis. All
information is updated quarterly; i.e., for each diagnosis
or prescription the quarter is documented in the data-
base, rather than the actual prescription date. Prescrip-
tions are only recorded in the database if they are filled
at the pharmacy. The International Statistical Classifica-
tion of Diseases and Related Health Problems termin-
ology (ICD-10-GM) was used for coding diagnoses and
the Anatomical Therapeutic Chemical classification sys-
tem (ATC) for coding drugs [22,23]. The study period
included the years 2004–2008. All analyses were per-
formed using anonymized administrative data only. Thusan ethical approval is not needed in Germany. There
was neither a data protection nor a legal basis to ask for
an ethical review or approval. The data of the National
Association of Statutory Health Insurance Physicians of
Bavaria, Munich, Germany (KVB) was routinely col-
lected on a legal basis. All authors had direct access to
KVB anonymized raw data for statistical analyses. For
this project a written agreement was signed between the
Institute of Medical Information Sciences, Biometry, and
Epidemiology (LMU Muenchen) and the Bavarian
National Association of Statutory Health Insurance
Physicians. Finally, all analyses were performed based on
STROBE (“STrengthening the Reporting of OBserva-
tional studies in Epidemiology”) guidelines and the re-
searchers assured that data was handled properly and
stored on secured servers.
Patient population
Patients having at least one ICD-10-GM diagnostic code
of asthma (J45 (“Asthma”) and/or J46 (“Status asthmat-
icus”)) documented within the study period and at least
one prescription of the following respiratory drugs
within the study period were included: salmeterol (ATC
code: R03AC12), formoterol (R03AC13), salmeterol and
fluticasone (R03AK06), formoterol and beclometasone
(R03AK27), formoterol and budesonide (R03AK28),
beclometasone (R03BA01), budesonide (R03BA02), flu-
nisolide (R03BA03), betamethasone (R03BA04), flutica-
sone (R03BA05), triamcinolone (R03BA06), mometasone
(R03BA07), and ciclesonide (R03BA08). The index date
was set as the quarter of the year of the first prescription
of a drug of interest in the study period. Patients with an
additional diagnosis of COPD (ICD-10-GM: J44 [“Other
chronic obstructive pulmonary disease”]) were consid-
ered as patients with asthma-COPD overlap syndrome
(ACOS).
Definition concomitant usage of LABA and ICS
If a patient received a fixed combination drug containing
LABA and ICS, the respective quarter of the year was
considered as a quarter with concomitant usage of
LABA and ICS (irrespective of any other drugs). Con-
comitant usage of LABA and ICS could also be assured
by prescribing both compounds separately, but in a close
temporal relationship (usually at the same day in clinical
routine). Taking into account a quarterly documentation
of prescribed drugs, a separate prescription of both a
LABA and an ICS compound was considered as con-
comitant usage of LABA and ICS if given in one quarter
(irrespective of any other drugs). According to the pat-
tern of LABA and ICS prescriptions, patients were
assigned to the following five mutually exclusive categor-
ies: “concomitant LABA and ICS users”, “switchers”,
“non-concomitant LABA and ICS users”, “LABA users
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“Switchers” were defined as patients with at least one
prescription of concomitant LABA and ICS (fixed dose
or separate prescription) in at least one quarter and at
least one LABA prescription without ICS in at least one
other quarter within a particular calendar year.
In a subgroup analysis, the following further stratifi-
cation were performed for the category “concomitant
LABA and ICS users”: i) patients receiving LABA and
ICS only in fixed inhalers (“combined inhaler”), ii) pa-
tients receiving LABA and ICS only in separate in-
halers (“separate inhalers”); iii) patients with
combinations (i.e., patients with at least one prescrip-
tion of a fixed LABA/ICS device, and in addition a
separate ICS- or a non-fixed LABA/ICS-prescription
in the same or another quarter of the respective calen-
dar year; “combinations”). All assignments to treat-
ment groups were made on a calendar year basis.
Statistical analysis
Annual period prevalence rates (PPRs) were calculated
using the number of patients with at least one pre-
scription of interest during the year of interest (nu-
merator) divided by the total number of compulsorily
insured Bavarians at midyear of the year of interest
(July, 1; denominator) [24]. Annual PPRs per 10,000
persons were calculated stratified by age (ten-year age
groups [0–9 years, 10–19 years, 20–29 years, […], 90+
years]), sex, and compound. For the five patient cat-
egories (“concomitant LABA and ICS users”,
“switchers”, “non-concomitant LABA and ICS users”,
“LABA users without ICS”, and ”ICS users without
LABA”) and the subgroup categories “combined in-
halers”, “separate inhalers”, and “combinations” the
number of patients and proportions were calculated
and stratifications by age, sex, and calendar year wereTable 1 Treatment categories
At least one prescription in at least one quarter
within a particular calendar year
Category LABA & ICS (fixed or non-


















*in up to all quarters of a particular calendar year, **except from the quarters
with a LABA only prescription in up to all quarters of a particular
calendar year.performed. All time trend analyses were performed using
the Cochrane Armitage test. All statistical calculations
were conducted using IBM SPSS Statistics Version 20.0
and GNU R Version 3.0.1 (http://www.r-project.org/).
Results
Period prevalence rates
Within the study period, the highest annual PPRs were
found for budesonide (between 75.6 and 90.6 per 10,000
persons) and the fixed combination of salmeterol/flutica-
sone (between 62.1 and 73.1 per 10,000 persons). In con-
trast, the lowest PPRs were observed for mometasone
(between 0.1 and 1.8 per 10,000 persons, Additional file 1:
Table S1). From 2004 to 2008, a significant increase in PPRs
was revealed for formoterol, fixed combinations of salme-
terol/fluticasone, formoterol/beclometasone, formoterol/
budesonide, and the ICS beclometasone and budesonide.
For all remaining drugs including salmeterol, a decrease
was found between 2004 and 2008 (all p-values <0.0001;
Figure 1). In addition, a slight decrease was found for sal-
meterol/fluticasone (between 2005 and 2008), and for for-
moterol and formoterol/budesonide (between 2007 and
2008).
Analysis of concomitant LABA and ICS usage
In total, 307,358 patients (approximately 2.9% out of all
insured people) with a documented diagnosis of asthma
or status asthmaticus were treated with at least one drug
of interest in 2008. The highest proportion (57.6%) of
patients was classified as “concomitant LABA and ICS
users” followed by “ICS users without LABA” (31.4%,
Table 2).
The proportion of asthma patients classified as “con-
comitant LABA and ICS users” increased from 52.0%
(2004) to 57.6% (2008, p < 0.0001), whereas the pro-
portion of patients classified as “LABA users without
ICS” decreased from 2004 onwards (2004: 6.5%; 2008:
5.4%, p < 0.0001). The proportion of “switchers” de-
creased slightly during the study period (2004: 5.4%;
2008: 4.8%, p < 0.0001) and the proportion of “non-
concomitant LABA and ICS users” increased slightly
during the study period (2004: 0.55%; 2008: 0.63%, p =
0.0020). For patients classified as “ICS users without
LABA”, we found a decrease within the study period
(2004: 35.6%; 2008:31.4%, p < 0.0001, Table 3).
The age and sex distribution (for the year 2008) for
each treatment category is presented in Table 2. The
mean age was the lowest in the “ICS users without
LABA” group with 37.5 (standard deviation (SD): 24.9)
years and the highest in the “switchers” group with 59.1
(SD: 17.8) years. In each group, more than half of all pa-
tients were females. In the “non-concomitant LABA and
ICS users” group, the proportion of females was the
highest (61.2%).
Figure 1 Annual period prevalence rates per 10,000 persons stratified by compound between 2004 and 2008.
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prescription without concomitant ICS (combined ana-
lysis of “LABA users without ICS”, “non-concomitant
LABA and ICS users”, “switchers”) was the lowest (1.3%)
in the age group 0–9 years, increased continuously over
the age groups, peaked in patients aged 80–89 years
(19.1%) and was followed by a small decrease for pa-
tients in the age group “90+” years (18.8%, Table 4). Re-
garding sex-related differences, the proportion of
patients with at least one LABA prescription without
concomitant ICS was slightly higher in men reaching
more than 20% in men aged over 70 years (70–79 years:
20.3%, 80–89 years: 21.3%, “90+”: 21.4%; Table 4). In
these elderly male patients, a concomitant diagnosis of
COPD (i.e. asthma-COPD overlap syndrome) was
present in 76.8% (Additional file 1: Table S2).Table 2 Age and sex distribution for the different treatment
“non-concomitant LABA and ICS users”, “LABA users without














1,184 (61.2%Concomitant LABA and ICS users – fixed combination
versus separate inhalers
Out of all “concomitant LABA and ICS users”, the pro-
portion of patients receiving LABA and ICS only in a
fixed inhaler device (“combined inhaler”) was high and
increased significantly from 82.2% to 85.7% within the
study period (p < 0.0001, Table 5).
The fraction of patients receiving at least one prescrip-
tion of a fixed LABA/ICS device, and in addition a sep-
arate ICS- or a non-fixed LABA/ICS-prescription
(“combinations”) decreased from 5.7% to 4.9% (p <
0.0001). On the other hand, patients classified as “con-
comitant LABA and ICS users” receiving LABA and ICS
only in separate inhalers decreased significantly from
12.1% to 9.5% (p < 0.0001, Table 5). The proportion of
those patients with two separate inhalers was highest ingroups (“concomitant LABA and ICS users”, “switchers”,
ICS”, “ICS users without LABA”) for the year 2008




16,749 (5.4%) 96,615 (31.4%)
58.0 ± 19.3 37.5 ± 24.9
) 8,705 (52.0%) 52,907 (54.8%)
Table 3 Proportion of patients stratified by treatment group (“concomitant LABA and ICS users”, “Switchers”,
“non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the years 2004
to 2008
Year
2004 2005 2006 2007 2008
Concomitant LABA and ICS users 123,873 (52.0%) 152,857 (54.6%) 152,418 (53.3%) 172,225 (55.3%) 177,159 (57.6%)
Switchers 12,785 (5.4%) 13,266 (4.7%) 14,207 (5.0%) 14,446 (4.6%) 14,899 (4.8%)
Non-concomitant LABA and ICS users 1,314 (0.6%) 1,686 (0.6%) 1,992 (0.7%) 1,896 (0.6%) 1,936 (0.6%)
LABA users without ICS 15,612 (6.5%) 19,200 (6.9%) 18,193 (6.4%) 17,810 (5.7%) 16,749 (5.4%)
ICS users without LABA 84,818 (35.6%) 92,970 (33.2%) 99,334 (34.7%) 105,252 (33.8%) 96,615 (31.4%)
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no differences were found for sex (Table 6).
Discussion
In our study, we found a slightly improved guideline ad-
herence in asthma patients in terms of i.) a moderate in-
crease of concomitant LABA and ICS prescriptions
(including both fixed combination drugs and separate
drugs) and ii.) a slight increase of LABA/ICS fixed com-
bination drugs between 2004 and 2008. Nevertheless, a
relevant number of patients received LABA at least in
one quarter without a concomitant ICS prescriptionTable 4 Proportion of patients stratified by age group, sex, a













































































































































*LABA/ICS treatment categories percentage values were calculated for each age gro(2004: 12.5%; 2008: 10.9% [including switchers, non-
concomitant LABA/ICS users, LABA users without
ICS]) or received non-fixed LABA/ICS treatment (2004:
12.1%; 2008: 9.5% [concomitant LABA and ICS users re-
ceiving LABA and ICS in separate inhalers]). Both issues
were most frequently present in elderly men.
LABA usage & Non-concomitant LABA/ICS usage
For formoterol we found a PPR increase between 2004
and 2007 followed by a slight decrease in 2008 whereas
for salmeterol, a distinct year-by-year decrease was
found between 2004 and 2008. Despite the fact, that thend treatment group (“concomitant LABA and ICS users”,










































































































































up and sex separately.
Table 5 “Concomitant LABA and ICS users” stratified by inhaler type for the years 2004 to 2008: “Combined Inhalers”,
“Separate Inhalers”, “Combinations”
Year
2004 2005 2006 2007 2008
Combined inhalers [fixed LABA/ICS] 101,814 (82.2%) 126,347 (82.7%) 126,301 (82.9%) 145,464 (84.5%) 151,784 (85.7%)
Separate inhalers [non-fixed LABA/ICS] 15,044 (12.1%) 18,490 (12.1%) 17,767 (11.7%) 17,930 (10.4%) 16,750 (9.5%)
Combinations 7,015 (5.7%) 8,020 (5.2%) 8,350 (5.5%) 8,831 (5.1%) 8,625 (4.9%)
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LABA in general as a drug class for which concomitant
ICS prescribing is needed [7], our data cannot exclude a
shift in LABA prescriptions in terms of stopping salme-
terol and initiating formoterol prescribing (without ICS)
in individual patients. For formoterol, an earlier onset of
bronchodilative effects compared to salmeterol is well-
known [20] and might explain a switch from salmeterol
to formoterol. However, a lacking prescribing of ICS to
asthma patients receiving formoterol has to be consid-
ered as guideline-violating prescription behaviour, too.
By conducting a combined analysis of formoterol and
salmeterol, we found a PPR increase between 2004 (45.2
per 10,000 persons) and 2008 (50.6 per 10,000 persons;
data not shown). Furthermore, only a small proportion
of patients received LABA without ICS (“switchers”,
“non-concomitant LABA and ICS users” and “LABA
users without ICS”) and the proportion of patients clas-
sified into these categories decreased between 2004 and
2008.
Similar to our combined analysis of formoterol and
salmeterol, [19] a slight increase of the absolute number
of LABA prescriptions was found in Italian asthma pa-
tients between 2006 and 2008. On the other hand, the
proportion of asthmatic children receiving LABATable 6 Concomitant LABA and ICS users stratified by age gr





Age group Male Female Male Female
0-9 3,262 (76.9%) 1,735 (75.8%) 219 (5.2%) 135 (5.9
10-19 9,121 (88.2%) 6,208 (87.9%) 550 (5.3%) 422 (6.0
20-29 6,052 (90.9%) 7,208 (89.9%) 436 (6.5%) 525 (6.6
30-39 7,053 (88.5%) 9,034 (87.2%) 669 (8.4%) 885 (8.5
40-49 10,015 (87.1%) 14,110 (86.0%) 1,102 (9.6%) 1,515 (9
50-59 8,777 (85.1%) 13,239 (84.8%) 1,120 (10.9%) 1,624 (1
60-69 10,454 (83.7%) 14,200 (84.1%) 1,545 (12.4%) 1,906 (1
70-79 9,428 (83.5%) 12,121 (84.5%) 1,368 (12.1%) 1,594 (1
80-89 3,469 (85.2%) 5,712 (86.1%) 433 (10.6%) 650 (9.8
90+ 178 (87.3%) 408 (87.7%) 17 (8.3%) 35 (7.5%
Total 67,809 (85.7%) 83,975 (85.6%) 7,459 (9.4%) 9,291 (9
*Concomitant LABA/ICS treatment categories percentage values were calculated fordecreased distinctly between 2001 and 2006 in a Scottish
study [13]. Regarding the United States, the proportion
of treatment visits with a LABA prescription without
concomitant steroids decreased between 2004 and 2008
and reached less than 1% in 2008 [25]. Our data suggest
a higher proportion of patients receiving LABA without
ICS but methodological differences might have contrib-
uted to these discrepant results. Whereas Higashi et al.
[25] calculated the proportion of visits for a particular
prescription category out of all visits (including visits
without LABA or ICS prescriptions) we analysed the
proportion of a particular patient category based on pre-
scriptions within one year out of all patients having at
least one prescription of interest not mentioning the
number of treatment visits.
Concomitant LABA/ICS usage & Fixed LABA/ICS
combination drugs
In our study, the proportion of concomitant LABA/ICS
users increased from 52.0% to 57.6% between 2004 and
2008. The observed increase could be related to an in-
creased prescribing of i.) ICS to patients receiving
LABA, ii.) LABA to patients receiving ICS, or iii.) fixed
LABA/ICS combinations. It is worth mentioning, that
all three potential changes in prescription behaviouroup, sex, and inhaler type (“Combined Inhalers”,
Combinations All concomitant
LABA/ICS categories
Male Female Male Female
%) 761 (17.9%) 418 (18.3%) 4,242 (100%) 2,288 (100%)
%) 676 (6.5%) 430 (6.1%) 10,347 (100%) 7,060 (100%)
%) 172 (2.6%) 281 (3.5%) 6,660 (100%) 8,014 (100%)
%) 250 (3.1%) 444 (4.3%) 7,972 (100%) 10,363 (100%)
.2%) 386 (3.4%) 788 (4.8%) 11,503 (100%) 16,413 (100%)
0.4%) 413 (4.0%) 748 (4.8%) 10,310 (100%) 15,611 (100%)
1.3%) 489 (3.9%) 779 (4.6%) 12,488 (100%) 16,885 (100%)
1.1%) 495 (4.4%) 625 (4.4%) 11,291 (100%) 14,340 (100%)
%) 169 (4.2%) 270 (4.1%) 4,071 (100%) 6,632 (100%)
) 9 (4.4%) 22 (4.7%) 204 (100%) 465 (100%)
.5%) 3,820 (4.8%) 4,805 (4.9%) 79,088 (100%) 98,071 (100%)
each age group and sex separately.
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proportion of patients with fixed LABA/ICS combin-
ation, we found an increase between 2004 and 2008
(82.2% versus 85.7%) out of all “concomitant LABA and
ICS users”. In comparison [25], LABA and ICS were pre-
scribed concomitantly (fixed combination drug and sep-
arate compounds) in the United States in approximately
20% to 30% of asthma treatment visits. Out of these
patients, 99% received a fixed combination of LABA/
ICS [25].
Regarding a compound specific analysis of fixed com-
bination drugs, we found a PPR increase of between
12.1% (salmeterol/fluticasone) and 49.8% (formoterol/
beclometasone [2007–2008]) within the study period. In
comparison, prescriptions of fixed salmeterol/flutica-
sone combination for Italian asthma patients increased
between 2006 and 2008 by 45% whereas for formoterol-
containing fixed combinations, a much more pro-
nounced increase by 137% was found [19]. In a
combined analysis of salmeterol- and formoterol-
containing fixed combinations, more than a doubling
was found for the proportion of children receiving
LABA/ICS in Scotland between 2001 and 2006 [13].
On a European level [26], a 50% increase of fixed
LABA/ICS combination drug prescriptions was found
between 2005 and 2009.
Regarding age- and sex-stratified analyses (year 2008),
the highest proportion of patients with at least one
LABA prescription without concomitant ICS (combined
analysis of “LABA users without ICS”, “non-concomitant
LABA and ICS users”, “switchers”) was found in elderly
men. The “lack” of ICS prescribing in these elderly men
receiving LABA might be related to a relevant COPD
drug burden (i.e. asthma-COPD overlap syndrome).
However, not prescribing ICS to ACOS patients on a
regular base might be reasonable regarding most recent
data [27].
Gap between guidelines/regulatory decisions and clinical
practice
The knowledge gap between research and clinical prac-
tice is a well-known problem and a wide range of inter-
ventions has been evaluated. To sum up the available
evidence, multifaceted, interactive approaches (e.g. au-
dits and feedback, workshops, reminders) seems to be
more effective than passive, single interventions (e.g.
educational materials [28,29]). For asthma, several strat-
egies for improving knowledge translation have been
evaluated. For example, a multiple level intervention was
conducted in Canada including the individual patient,
the practice, and the health system level. By implement-
ing six guideline-based care elements including e.g. spir-
ometry measurement, asthma controller therapy, and
self-management action plans, a significant improvementof relevant clinical endpoints (e.g. reduced number of ur-
gent / emergent healthcare visits [30]) was found. Further-
more, the proportion of patients receiving LABA/ICS
combination therapy increased, but unfortunately, results
for LABA monotherapy were not reported in this study.
Most recently, electronic tools were examined to promote
knowledge translation at physician and patient level, but
further studies are needed to clarify the impact of these
approaches [31,32] in particular regarding their impact on
improving guideline-adherent prescription behaviour.
In Germany, a nationwide disease management pro-
gram (DMP) for patients with asthma was implemented
in 2006 including e.g. regular visits, individual action
plans, and regular feedback to coordinating general prac-
titioners [33]. By analysing annual trends of asthma
treatment for patients included in this DMP between
2006 and 2010, a guideline-adherent prescribing was
found in the majority of patients. Nevertheless, a small
but slightly increasing proportion of patients has re-
ceived LABA monotherapy (2006: 2.1%, 2010: 3.5%). As
already discussed for our study, this finding could be re-
lated to a concomitant diagnosis of COPD which was
present in 2.8% to 5.2% of DMP patients [33].
Regarding the impact of regulatory actions on pre-
scribing behaviour in daily practice, only a few well-
conducted studies are available. In a systematic review,
no final conclusion regarding the impact of safety-
related regulatory actions could be made due to inad-
equate study designs and heterogeneity in analyses and
outcome measures [34]. In particular, confounding fac-
tors are of outstanding importance but difficult to adjust
for hampering a valid estimate of the actual impact of a
particular regulatory action. By comparing the impact of
different information included in a “Dear doctor” letter,
“simple” information (dose limit) has been considered by
physicians more frequently compared to “complex” in-
formation (QT prolongation due to drug-drug interac-
tions) [35]. Taken into account the more or less “simple”
message of asthma guidelines and SMART-related regu-
latory actions, a guideline adherent prescribing of LABA
and ICS seems achievable. Due to confounding factors
(e.g. disease management program for asthma patients)
and the complexity of treatment decision making, we
were unable to quantify the actual impact of the SMART
trial publication and/or SMART-related drug regulatory
actions on prescribing behaviour.
Strengths & limitations
Our study has several strengths worth noting. First, the
database covers a population of about 10.5 million
people and represents 85% of the inhabitants of Bavarian
(the largest federal state of Germany). In addition, we
were able to perform detailed analyses focusing on the
presence or absence of concomitant ICS prescriptions in
Rottenkolber et al. BMC Pulmonary Medicine  (2015) 15:55 Page 8 of 10asthma patients receiving LABA. Furthermore, due to a
5-year period, we could analyse trends in PPRs as well
as in LABA- and ICS-related prescription behaviour
after the SMART trial. Despite these strengths, there are
also several limitations regarding our study. Firstly, our
analysis was limited to the years 2004 to 2008 and more
recent changes in prescription behaviour should be
taken into account. By comparing nationwide drug pre-
scription data for the years 2008 and 2013 (irrespective
of indication), for salmeterol a 72.5% decrease (2008:
9.1 Mio. DDD, 2013: 2.5 Mio. DDD), for formoterol a
22.2% increase (2008: 99.1 Mio. DDD, 2013: 121.1 Mio.
DDD), for ICS a slight decrease of 4.0% (2008:
167.6 Mio. DDD, 2013: 160.9 Mio. DDD), and for fixed
combinations of LABA/ICS a distinct increase of 28.7%
(2008: 255.8 Mio. DDD, 2013: 329.2 Mio. DDD) were
found [36,37]. Since our main aim was to conduct a
comprehensive and more detailed analysis of LABA- and
ICS-prescribing in asthma patients after the SMART
trial, we decided to use a period covering most factors
potentially influencing drug prescribing including publi-
cation and dissemination of SMART results and
SMART-related drug regulatory actions. Secondly, the
prescriptions are documented on a quarterly basis in the
database meaning that all LABA and ICS prescriptions
were counted as concomitant if they occurred in the
same quarter irrespective of the actual prescription date.
Hence, the proportion of concomitant LABA/ICS users
is likely to be overestimated in our study. Thirdly, only
patients with compulsory insurance are covered in our
analyses and thus, by excluding patients with a private
health insurance, a socioeconomic bias on our study re-
sults cannot be excluded. Fourthly, this study covers a
Southern region of Germany and hence, generalizability
of results to other German regions or to other countries
is limited as reported for several other studies, too
[38,39]. However, by taking into account methodological
differences, PPRs for LABA, ICS, and fixed combination
of LABA/ICS found in our study showed a similar pat-
tern and trend compared to national drug consumption
data [36,40]. Fifthly, by using prescription data only, pre-
scribing quality can only roughly assessed due to missing
individual data important for a clinical decision (e.g.
lacking lung function parameter, detailed clinical history)
and a substantial proportion of patients potentially given
an incorrect diagnosis (i.e. asthma instead of COPD)
[41,42].
Conclusions
By analysing prescription data of a German population
covering 10.5 million subjects, we found a slightly in-
creased guideline adherence between 2004 and 2008. In
elderly men, the proportion of patients receiving LABA
and ICS non-concomitantly was highest but might bereasonable taking into account a concomitant diagnosis
of COPD (i.e. ACOS). Due to the complexity of factors
influencing prescription behaviour (e.g. guidelines, dis-
ease management programs), we were not able to quan-
tify the actual impact of the publication or dissemination
of the SMART trial results and/or related drug regula-
tory actions. Further studies are needed to analyse in de-
tail the impact of “milestone” trials and related drug
regulatory actions on real-life prescription behaviour.
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